March 3, 2020 - BioPharma Dive
Thermo Fisher Scientific plans to acquire Qiagen in a deal valued at $11.5 billion, the companies announced early Tuesday, putting a seal on will-they-won't-they M&A rumors first publicized last November.
Easily the largest deal the medtech industry has seen in 2020, the Waltham, Massachusetts-based life sciences giant is offering 39 euros, or about $43, per Qiagen share, representing a 23% premium. The approximately $11.5 billion price tag includes assumption of about $1.4 billion of net debt. The deal is expected to be finalized in the first half of 2021.
March 3, 2020 - Fierce Pharma
Back in 2017, GlaxoSmithKline initiated a strategic review of its cephalosporins antibiotics business shortly after Emma Walmsley took over as CEO. Though the British drugmaker didn’t go through with a selloff, that option is now back on the table.
GSK has tapped financial advisers to potentially offload its cephalosporin portfolio, which includes Zinnat and Fortum, Bloomberg
reported
, citing people familiar with the matter.
March 2, 2020 - Fierce Biotech
Gilead has
struck
a deal to buy Forty Seven for $4.9 billion. The takeover will give Gilead control of midphase anti-CD47 antibody magrolimab that delivered data that impressed investors late last year.
Forty Seven set up shop in 2015 to build on evidence of the role of CD47 in immune evasion that Irv Weissman and his colleagues at Stanford University generated. The evidence suggested that drugging CD47 could neutralize a key mechanism tumors use to avoid being attacked by the immune system, thereby unlocking opportunities for combination therapies in multiple indications.
March 2, 2020 - Fierce Pharma
In its push to flush cash into a red-hot oncology field, AstraZeneca has made a gung-ho attempt to sell off non-core and underperforming assets in its portfolio. Only a week after the British drugmaker pawned off one of its gastrointestinal meds, AstraZeneca is back on the auction block with a suite of its hypertension drugs.
AstraZeneca has
sold
global commercial rights for hypertension meds Inderal, Tenormin, Tenoretic, Zestril and Zestoretic to Atnahs Pharma to the tune of $350 million and future milestone payments, the drugmaker said Monday.
March 2, 2020 - Fierce Pharma
In two deals that help Takeda move closer to its debt-lowering goal, the Japanese pharma is offloading some non-core Latin American brands to Brazil’s Hypera Pharma and just sold its old U.S. headquarters to Horizon Therapeutics.
Takeda has
agreed to sell
18 branded prescriptions and consumer health drugs in Latin America to Brazil’s Hypera Pharma for $825 million, the company said Monday.
